Cathy Eng

1 month ago | ajmc.com | Maggie L. Shaw |Cathy Eng

Earlier this year, for a oncology-focused Institute for Value-Based Medicine® event, The American Journal of Managed Care® partnered with several prominent health care institutions from across the Nashville region to elevate value in cancer care by discussing the roles that academic, hospital, and community partnerships; precision medicine; pharmacy; and health equity fulfill when delivering care in the oncology space.

2 months ago | oncodaily.com | Scott Kopetz |Cathy Eng

This event featured the latest research, treatments, and strategies in the fight against GI cancers. People had the chance to attend expert-led sessions on emerging therapies, clinical breakthroughs, and multidisciplinary approaches to patient care. For more details on the program, check out the official Meeting Announcement and download the full schedule. Our team at OncoDaily has selected a few highlights from ASCO GI 2025 that you should not miss:Marwan G.

Jan 25, 2025 | nature.com | Scott Kopetz |Takayuki Yoshino |Eric Van Cutsem |Cathy Eng |Harpreet Wasan |Jayesh Desai | +9 more

Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC. The dual primary endpoint of progression-free survival is event driven; data were not mature at data cutoff. BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253; 99.8% CI: 1.019–5.855; one-sided P = 0.0008). Median duration of response was 13.9 versus 11.1 months. At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318–0.691; repeated CI: 0.166–1.322). Serious adverse event rates were 37.7% versus 34.6%. The safety profiles were consistent with those known for each agent. BREAKWATER demonstrated a significantly improved response rate that was durable for first-line EC+mFOLFOX6 versus SOC in patients with BRAF V600E mCRC. ClinicalTrials.gov identifier: NCT04607421 . As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF inhibitor encorafenib, the anti-EGFR monoclonal antibody cetuximab and chemotherapy mFOLFOX6 versus investigator’s choice of chemotherapy with or without bevacizumab, leading to an improved objective response rate, with the dual primary endpoint of progression free survival still maturing.

Sep 30, 2024 | onclive.com | Cathy Eng

CommentaryVideoSeptember 30, 2024Author(s):Cathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm. Cathy Eng, MD, FACP, FASCO, David H.

Jun 5, 2024 | medscape.com | Benjamin L. Schlechter |Cathy Eng

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter. Welcome to Medscape's InDiscussion series on colorectal cancer. Today we're discussing treatment options for refractory colorectal cancer with Dr Cathy Eng.